Scott H. Donaldson, MD

Professor of Medicine, Division of Pulmonary Diseases and Critical Care Medicine
Associate Director, Marsico Clinical and Translational Research Center

Specialty Areas: Cystic fibrosis (adults), Bronchiectasis, COPD

Chronology: BS Biology: University of Michigan, 1986; MD: University of Michigan, 1990; Internal Medicine Internship/Residency: Dartmouth-Hitchcock Medical Center, 1990-1993; Pulmonary/Critical Care Fellowship: University of North Carolina, 1993-1996; Research Fellow: University of North Carolina, 1996-1998; Research Assistant Professor of Medicine: 1998-2003; Assistant Professor of Medicine (tenure track): 2003-2009; Associate Professor of Medicine: 2009-2018; Associate Director, UNC Adult CF Care Center: 2006-2014; Director, UNC Adult CF Care Center: 2014-present; Medical Director, Adult CF Respiratory Therapy Services: 2012 – present; Medical Director, UNC Pulmonary Clinics: 2012-present; Associate Director, UNC Clinical and Translational Research Center (CTRC): 2014-present, Professor of Medicine: 2018 – present

Dr. Donaldson’s clinical and research interests are focused on adults with cystic fibrosis (CF). His research has added to our understanding of the processes that regulate the volume of liquid that bathes airway surfaces, and control rates of mucus clearance from the lung. In particular, he is involved in the development of new therapies that improve mucus clearance from the lung in CF, while investigating whether similar approaches may also be beneficial in patients with the chronic bronchitis form of COPD. Dr. Donaldson also leads a multidisciplinary team that cares for more than 250 adults with CF, who are actively engaged in improving care processes through quality improvement principles.

Selected Bibliography (reverse chronological order):

  1. Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2015 Aug 25.
  2. Bennett WD, Xie M, Zeman K, Hurd H, Donaldson S. Heterogeneity of Particle Deposition by Pixel Analysis of 2D Gamma Scintigraphy Images. J Aerosol Med Pulm Drug Deliv. 2015 Jun;28(3):211-8.
  3. Bennett WD, Wu J, Fuller F, Balcazar JR, Zeman KL, Duckworth H, Donn K, O’Riordan TG, Boucher RC, Donaldson SH. Duration of Action of Hypertonic Saline on Mucociliary Clearance in the Normal Lung. J of Appl Physiol (1985). 2015 Apr 24:jap.00404.2014. doi: 10.1152/japplphysiol.00404.2014. [Epub ahead of print]
  4. Tiddens HA, Puderbach M, Venegas JG, Ratjen F, Donaldson SH, Davis SD, Rowe SM, Sagel SD, Higgins M, Waltz DA. Novel outcome measures for clinical trials in cystic fibrosis. Pediatr Pulmonol. 2014 Dec 30. doi: 10.1002/ppul.23146.
  5. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
  6. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW. Clinical Mechanism of the CFTR Potentiator Ivacaftor in G551D-Mediated Cystic Fibrosis. Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84
  7. Henderson AG, Ehre C, Button B, Abdullah L, Cai L, Leigh M, DeMaria G, Matsui H, Donaldson SH, Davis CW, Sheehan J, Boucher RC, and Kesimer M. Mucins are Abnormally Concentrated in CF Respiratory Secretions: Role in Disease Pathogenesis. J Clin Invest. 2014 Jun 2. pii: 73469. doi: 10.1172/JCI73469. [Epub ahead of print]
  8. Goralski, JL, Donaldson SH. Hypertonic Saline for Cystic Fibrosis: Worth It’s Salt? Expert Rev Respir Med. 2014; Expert Rev Respir Med. 2014 Jun;8(3):267-9.
  9. Hill DB, Vasquez PA, Mellnik J, McKinley SA, Vose A, Mu F, Henderson AG, Donaldson SH, Alexis NE, Boucher RC, Forest MG. A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease. PLoS One. 2014 Feb 18;9(2):e87681.
  10. Donaldson SH and Galietta L: New Pulmonary Therapies Directed at Targets other than CFTR. Cold Spring Harb Perspect Med. 2013 Jun 1;3(6).
  11. Clancy JP, Szczesniak RD, Ashlock MA, Ernst SE, Fan L, Hornick DB, Karp PH, Khan U, Lymp J, Ostmann AJ, Rezayat A, Starner TD, Sugandha SP, Sun H, Quinney N, Donaldson SH, Rowe SM, Gabriel SE. Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function. PLoS One. 2013 Sep 10;8(9):e73905
  12. Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One. 2013 Jul 26;8(7):e66955.
  13. Bennett WD, Laube BL, Corcoran T, Zeman K, Sharpless G, Thomas K, Wu J, Mogayzel PJ Jr, Pilewski J, Donaldson S. Multisite comparison of mucociliary and cough clearance measures using standardized methods. J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):157-64.
  14. Zeman KL, Wu J, Donaldson SH, Bennett WD. Comparison of (133)Xenon Ventilation Equilibrium Scan (XV) and (99m)Technetium Transmission (TT) Scan for Use in Regional Lung Analysis by 2D Gamma Scintigraphy in Healthy and Cystic Fibrosis Lungs. J Aerosol Med Pulm Drug Deliv. 2013 Feb 19.
  15. Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax. 2012 Oct;67(10):882-90.
  16. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8.
  17. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, Deboeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012 Jan;67(1):12-18.
  18. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 2011 Nov 3;365(18):1663-72.
  19. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation. N. Engl J Med 2010 Nov 18;363(21):1991-2003.
  20. Stressmann FA, Rogers GB, Klem ER, Lilley AK, Donaldson SH, Daniels TW, Carroll MP, Patel N, Forbes B, Boucher RC, Wolfgang MC, Bruce KD. Analysis of the bacterial communities present in the lungs of Cystic Fibrosis patients from American and British centers. J Clin Microbiol. 2010 Nov 10
  21. Tiddens HAWM, Donaldson SH, Rosenfeld M, Paré PD. Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively? Ped Pulm 2010 Feb;45(2):107-17.
  22. Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, Stutts MJ, Tarran R. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11412-7.
  23. Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and Tolerability of Inhaled Hypertonic Saline in Young Children with Cystic Fibrosis. Ped Pulm. 2008, 43(11):1100-6.
  24. Donaldson SH. Mucociliary Clearance: A Target for Treatment in CF and COPD. Respir Drug Deliv. 2008 Vol 1 (2008):29-36.
  25. Rollins BM, Burns M, Coakley RD, Chambers LA, Hirsh AJ, Clunes MT, Lethem MI, Donaldson SH, Tarran R. A2B Adenosine Receptors Regulate the Mucus Clearance Component of the Lungs Innate Defense System. Am J Respir Cell Mol Biol. 2008, Aug;39(2):190-7.
  26. Donaldson SH. Hydrator Therapies for Cystic Fibrosis Lung Disease. Ped Pulm. 2008, 43:S18-S23.
  27. Esther CR, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Pedrosa Ribiero CM, Moore CG, Davis SD, and Boucher RC. Extracellular Purines are Biomarkers of Neutrophilic Airway Inflammation. Eur Respir J 2008, May;31(5):949-56.
  28. Donaldson S, and Boucher RC. Sodium Channels in Cystic Fibrosis. Chest. 2007, 132(5):1631-6.
  29. Donaldson SH, Corcoran TE, Laube BL, and Bennett WD. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc. ATS 2007, 4(4):399-405.
  30. Tarran R, Donaldson S, and Boucher RC. Rationale for hypertonic saline for cystic fibrosis lung disease. Seminary in Respiratory and Critical Care Medicine 2007, 28(3):295-302.
  31. Kennedy MP, Coakley RD, Donaldson SH et al. Burkholderia gladioli: Five year experience in a cystic fibrosis and lung transplantation center. J Cyst Fibros 2007;6(4):267-73.
  32. Donaldson SH, and Boucher RC. Pathophysiology of Cystic Fibrosis. Ann Nestle’ [Engl] 2006;64:101-108.
  33. Tarran R, Trout L, Donaldson SH, and Boucher RC. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 2006; 127(5):591-604.
  34. I. Aziz, J. A. Kastelik, S. Zarogiannis, C. Hatzoglou, K. Gourgoulianis, R. Kuver, S. P. Lee, P. T.P. Bye, M. R. Elkins, S. H. Donaldson, R. Tarran, R. C. Boucher, and F. Ratjen. N. Engl. J. Med. 2006; 354(17): 1848 – 1851.
  35. Donaldson SH, Bennett W, Zeman K, Knowles MR, Tarran R, and Boucher RC. Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline. N. Engl. J. Med. 2006; 354(3):241-250.
  36. Donaldson SH and Boucher RC. Update on the Pathogenesis of Cystic Fibrosis Lung Disease. Curr Opp Pulm Med 2003; Nov;9(6):486-91.
  37. Donaldson S, Novotny D, Paradowski L, Aris R: Acute and chronic lung allograft rejection during pregnancy. Chest. 1996;110:293-296.
  38. Donaldson SH, Poligone, E, Stutts MJ. CFTR Regulation of ENaC. Methods Mol Med 2002; 70:343-364.
  39. Donaldson SH, Picher P, Boucher RC. Cell surface and secreted adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism in airways. Am J Respir Cell Mol Biol. 2002 Feb;26(2):209-15.
  40. Donaldson SH, Hirsh A, Li DC, Holloway G, Chao J, Boucher RC, Gabriel SE. Regulation of the Epithelial Sodium Channel by Serine Proteases in Human Airways. J Biol Chem 2002;277(10):8338-45.
  41. Donaldson SH, Lazarowski ER, Picher M, Knowles MR, Stutts MJ, and Boucher, RC. Basal Nucleotide Levels, Release, and Metabolism in Normal and Cystic Fibrosis Airways. Molecular Medicine. 2000; 6(11):969-982.
  42. Pinto-Powell R, Olivier KN, Marsh BJ, Donaldson S, Parker W, Boyle W, Knowles M, Magnusson M, von Reyn CF. Skin testing with Mycobacterium avium sensitin to identify infection with M. avium complex in cystic fibrosis. Clin. Inf. Dis. 1996;22:560-562.
scott-donaldson